Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Charles de Bock

Group Leader

Children's Cancer Institute Australia

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Cell Biology Cell Biology professors in Australia

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (11)

Hansen Kosasih

Children's Cancer Institute Australia

AUSTRALIA

View details

Hélène Gleitz

Assistant professor

Erasmus MC

NETHERLANDS

View details

Lev M. Kats

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA

View details

Paul Ekert

Group Leader, Translational Tumour Biology

Children's Cancer Institute Australia

AUSTRALIA

View details

Katherine Y. King

Baylor College of Medicine

UNITED STATES

View details

Daniel Thomas

University of Adelaide

AUSTRALIA

View details

Russell Pickford

UNSW Sydney

AUSTRALIA

View details

Heather Lee

University of Newcastle Australia

AUSTRALIA

View details

Yizhou Huang

University of New South Wales

AUSTRALIA

View details

Richard Lock

Head

Children's Cancer Institute Australia

AUSTRALIA

View details

Kellie Machlus

Associate Professor

Boston Children's Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Charles de Bock

Research Interests

Explore related searches

Articles (20)

IRF2BP2::JAK2 Defines a Novel Kinase-Activating Fusion in Pediatric T-Cell Acute Lymphoblastic Leukemia

The case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia

OutFOXing a FENDRR bender in T-ALL

Preclinical evaluation of the ROR1-targeting antibody–drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia

Building a transparent and functional lab culture: Guidelines for creating a Laboratory Handbook for principal investigators

A new KAT on the block rewrites the epigenetic script in menin inhibitor‐resistant leukemia

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal

Patient‐derived xenografts: Practical considerations for preclinical drug testing

TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia

FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome

Advice for effective leadership and hitting the ground running as a new group leader

Mastering fate: Redistributing a pioneer protein to rewrite leukemia's script

Less is more: Depleting myeloid‐biased HSCs to restore immune function

PU.1 eviction at lymphocyte-specific chromatin domains mediates glucocorticoid response in acute lymphoblastic leukemia

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

The tumor suppressor Fat1 is dispensable for normal murine hematopoiesis

Overcoming a T‐ALL order: A comprehensive study linking genomics to clinical outcomes

Selective targeting of malignant T cells

The landscape of alterations affecting epigenetic regulators in T‐cell acute lymphoblastic leukemia: Roles in leukemogenesis and therapeutic opportunities

Collaborators (11)

Hansen Kosasih

Hélène Gleitz

Lev M. Kats

Paul Ekert

Katherine Y. King

Daniel Thomas

Russell Pickford

Heather Lee

Yizhou Huang

Richard Lock

Kellie Machlus

Make your next move.